PCM
VTYX

Peregrine Capital Management’s Ventyx Biosciences VTYX Stock Holding History

Peregrine Capital Management’s Portfolio VTYX Stock Details VTYX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-94,565
Closed -$3.28M – 328
2023
Q3 		$3.28M Sell
94,565
-5,920
-6% -$205K 0.1% 241
2023
Q2 		$3.3M Buy
+100,485
New +$3.46M 0.09% 246

Other funds holding VTYX

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Peregrine Capital Management's VTYX Position: Q4 2023 in Review

Peregrine Capital Management sold out of Ventyx Biosciences (VTYX) in Q4 2023, closing a stake of 94,565 shares — an estimated $3.28M sold.

Peregrine Capital Management first reported a position in VTYX in Q2 2023 and held it in 2 quarters. The position peaked at $3.3M in Q2 2023. 121 funds tracked by Wall St. Rank hold VTYX as of Q4 2023.

  • Peregrine Capital Management reported no remaining Ventyx Biosciences position as of Q4 2023 after selling out during the quarter.
  • Peregrine Capital Management sold 94,565 Ventyx Biosciences shares in Q4 2023, an estimated $3.28M.
  • Peregrine Capital Management first reported a position in Ventyx Biosciences in Q2 2023 and held it in 2 quarters.
  • Peregrine Capital Management's Ventyx Biosciences position peaked at $3.3M in Q2 2023.
  • 121 funds tracked by Wall St. Rank held Ventyx Biosciences as of Q4 2023.

Based on Peregrine Capital Management's 13F filing for Q4 2023, filed 26 Jan 2024.